- First and Only Gel for Overactive Bladder
- Quick, convenient treatment option allows patients to treat OAB without
having to take a pill
OAKVILLE, ON, Sept. 12, 2012 /CNW/ - Watson Canada today announced that
Gelnique® (oxybutynin chloride gel), the first-ever topical gel for the
treatment of overactive bladder (OAB), is now available in Canada.
Gelnique provides patients with a novel alternative to current oral
treatment options, with a very low incidence of side effects, such as
Gelnique is a quick-drying, clear, and fragrance-free gel that is
applied once daily to the thigh, abdomen, upper arm or shoulder. A
one-gram dose of Gelnique is rubbed into the skin like any skin cream,
and delivers a constant dose of oxybutynin over a 24-hour period.
"Gelnique's novel gel formulation provides an important new option for
patients with OAB," says Dr. Sender Herschorn, Professor and Chair
University of Toronto Division of Urology. "Gelnique contains
oxybutynin, the same ingredient as many available oral therapies, which
has been well established as a safe and efficacious treatment for
OAB. However, because Gelnique is absorbed through the skin and not
taken by mouth, patients may experience limited anticholinergic side
Current oral therapies for OAB are often associated with troubling side
effects, such as severe dry mouth and constipation, often causing
patients to discontinue use. Unlike oral treatments, Gelnique is
delivered transdermally, and has been shown to cause few
anticholinergic adverse effects. In clinical trials with Gelnique, no
patients discontinued due to dry mouth.
MORE THAN AN INCONVENIENCE OR EMBARRASSMENT
Overactive bladder is a common, debilitating condition characterized by
a sudden, uncomfortable need to urinate even when the bladder isn't
full. It often results in an unexpected loss of urine, wetting
accidents and the associated embarrassment.
In Canada, nearly one in five people over the age of 35 suffer from
OAB. More than an inconvenience or embarrassment, OAB is associated
with increased health risks and decreased quality of life. Patients with OAB can also have higher rates of hypertension, obesity,
and even arthritis.
Although the prevalence of OAB is slightly higher in women, one in six
men suffers from OAB (21.2 per cent vs. 14.8 per cent).
OAB IMPACTS RELATIONSHIPS & QUALITY OF LIFE
Both men and women with OAB are significantly more likely to report
diminished sexual activity and enjoyment of sex because of urinary
OAB has been shown to reduce sexual desire and the ability to achieve
orgasm in women, and can be associated with increased prevalence of erectile dysfunction
and reduced sexual enjoyment in men. Patients' partners report that OAB fosters significant emotions,
including embarrassment, anxiety, anger, worry, frustration, and
"Overactive bladder not only impacts overall health, but also sexual
intimacy, romantic relationships, and self-confidence," says Maureen
McGrath, Nurse Continence Advisor. "All patients should speak to their physician about sexual health when
seeking a treatment for OAB as it can severely impact quality of life."
Gelnique is indicated for the treatment of OAB with symptoms of urge
urinary incontinence, urgency and frequency.
In a Phase 3, 12-week trial, one-gram, once-daily Gelnique was superior
to placebo at relieving OAB symptoms, including a reduction in
incontinence episodes and urinary frequency, and an increase in urine
void volume. The treatment was well tolerated in the study with a low
incidence of mostly mild side effects and no serious adverse events.
The most frequently reported treatment-related adverse events (>2 per
cent and greater than placebo) were dry mouth and application-site
reactions (5.4 per cent).
Additional pharmacology studies showed that showering one hour or later,
or applying oil-free sunscreen lotion 30 minutes before or after
Gelnique application, did not significantly alter the absorption of the
Gelnique significantly improved the quality of life domains of travel,
physical activity, social relationships and emotional health.
For full prescribing information, please visit WatsonPharmaCompany.ca.
ABOUT WATSON PHARMA COMPANY
Watson Pharma Company is the newly-formed Canadian subsidiary of Watson
Pharmaceuticals, Inc. Established in 2011 and headquartered in
Oakville, Ontario, it is engaged in the marketing, sale and
distribution of branded pharmaceutical products to the Canadian market.
Watson is focused on delivering innovative products that address key
therapeutic categories in Urology and Women's Health. As a subsidiary
of Watson Pharmaceuticals, it is supported by Watson's sophisticated
R&D and manufacturing capabilities, and one of the industry's leading
global supply chains. For press release and other company information,
visit Watson Pharma Company's website at www.WatsonPharmaCompany.ca
SOURCE: Watson Pharma Company
For further information:
416.413.4744 / Michelle.email@example.com